HOOKIPA Pharma Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- HOOKIPA Pharma Inc., a biopharmaceutical firm in the clinical stage, previously focused on developing immunotherapies for infectious diseases and cancers utilizing its distinct arenavirus platform. The company has since initiated a strategic process to voluntarily delist from Nasdaq and pursue liquidation, with a shareholder meeting scheduled for approval in July 2025. In October 2025, HOOKIPA completed the sale of its assets related to the HB-400 program for Hepatitis B and certain HB-500 assets for HIV to Gilead Sciences, Inc., transferring full ownership of these infectious disease programs. Regarding its oncology pipeline, clinical development for HB-200 (esebe-vec), an investigational immunotherapy for HPV16-positive cancers, was paused as of November 2024 due to a company restructuring. The HB-700 program, targeting KRAS-mutated cancers, received Investigational New Drug (IND) clearance in April 2024 and is considered Phase 1 ready, although its future development is affected by the company's liquidation plans. Additionally, the HB-300 program for prostate cancer saw its development activities halted in January 2024 to conserve capital. HOOKIPA Pharma Inc. was established in 2011 and maintains its headquarters in New York, New York.
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA
HOOKIPA Pharma Inc - FORM 8 (OPD)
HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements
Gilead backs proposed Poolbeg Pharma's proposed tie-up with HOOKIPA
Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA
HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment
Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.
HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet
HOOKIPA Pharma Announces Board of Directors Changes
HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights